Skip to main content
COO
NASDAQ Industrial Applications And Services

CooperCompanies Completes Strategic Review, Expands Buyback to $3B, Posts Q3 Beat

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$54.49
Mkt Cap
$12.381B
52W Low
$58.89
52W High
$89.83
52W Position info
7.5% below low
Off High info
39% below high
Rel. Volume info
3.8× avg
Market data snapshot near publication time

COO is trading near its 52-week low of $58.89 (7.5% below the low) on elevated volume (3.8× avg).

Summary

CooperCompanies reported Q3 revenue of $1.066 billion (up 1% y/y) and non-GAAP EPS of $1.15, completed its strategic review by retaining CooperSurgical, and expanded its share repurchase authorization from $2 billion to $3 billion.


Key Events · Earnings and Guidance · COO

  • Q3 Revenue Misses, EPS Beats

    Revenue of $1.066 billion rose 1% y/y but missed the $1.10 billion consensus; non-GAAP diluted EPS of $1.15 beat expectations, up 4% y/y.

  • Strategic Review Concludes: Keep CooperSurgical

    Board unanimously decided to retain CooperSurgical after evaluating a sale, citing a valuation disconnect from offers received due to competitive and litigation factors.

  • Buyback Authorization Expanded to $3B

    Board increased the share repurchase authorization from $2 billion to $3 billion; approximately $1.5 billion remains available after $339.1 million repurchased in Q3.

  • $307.2M One-Time Tax Benefit

    Favorable completion of a U.K. tax examination produced a $307.2 million discrete tax benefit, driving GAAP diluted EPS to $2.24 versus $0.49 a year ago.


Analysis · COO · Industrial Applications And Services

CooperCompanies delivered a mixed quarter — revenue missed consensus but non-GAAP EPS beat — while resolving a months-long strategic review by deciding to keep CooperSurgical and expanding its buyback authorization by $1 billion. The $307.2 million tax benefit is a one-time windfall that flatters GAAP results but does not reflect operating performance. The board's decision to retain CooperSurgical after evaluating a sale signals confidence in the business, but the disclosed 'valuation disconnect' from offers suggests bidders saw less value than management. The expanded buyback, with $1.5 billion remaining, gives management a tool to support the stock near its 52-week low.

How filings like this one have moved

In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, COO was trading at $54.49 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $12.4B. The 52-week trading range was $58.89 to $89.83. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

COO - Latest Insights

COO
Sep 09, 2026, 4:48 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $53.85
Real-time Price: $54.69 info
Change: +$0.840 (+2%) info
Market Cap: $12.381B info
COO
Sep 09, 2026, 4:31 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $53.80
Real-time Price: $54.69 info
Change: +$0.890 (+2%) info
Market Cap: $12.381B info
COO
Jun 05, 2026, 4:51 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $66.90
Real-time Price: $54.69 info
Change: -$12.21 (-18%) info
Market Cap: $12.381B info
COO
Jun 05, 2026, 4:47 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $66.90
Real-time Price: $54.69 info
Change: -$12.21 (-18%) info
Market Cap: $12.381B info
COO
Jun 04, 2026, 4:27 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $63.30
Real-time Price: $54.69 info
Change: -$8.61 (-14%) info
Market Cap: $12.381B info